Autologous IL-15/IL-21-armored Anti-glypican-3 CAR T-cells - CISMeF
Autologous IL-15/IL-21-armored Anti-glypican-3 CAR T-cellsNCIt concept
Preferred Label : Autologous IL-15/IL-21-armored Anti-glypican-3 CAR T-cells;
NCIt synonyms : Autologous IL-15/IL-21-armored Anti-GPC3 CAR T Cells; Autologous IL-15/IL-21-armored Anti-GPC3 CAR-expressing T-cells; IL-15/IL-21-armored Glypican-3-specific CAR-expressing Autologous T-cells; Autologous IL-15/IL-21-armored Anti-GPC3 CAR-T Cells; Autologous IL-15/IL-21-armored Anti-GPC3 CAR T-cells; 15.21.GPC3-CAR T Cells;
NCIt definition : A preparation of autologous T-lymphocytes that have been genetically modified to express
a chimeric antigen receptor (CAR) specific for glypican-3 (GPC3), interleukin-15 (IL-15)
and interleukin-21 (IL-21), with potential immunostimulating and antineoplastic activities.
Upon administration, autologous IL-15/IL-21-armored anti-GPC3 CAR T-cells specifically
target and bind to GPC3-expressing tumor cells, resulting in tumor cell lysis. GPC3,
a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed
on certain tumor cell types while minimally expressed on normal, healthy cells; GPC3
plays an important role in cellular proliferation and differentiation. The cytokines
IL-15 and IL-21 promote T-cell survival, expansion and persistence, which may potentiate
the immune response against tumor cells.;